NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell Ltd (NASDAQ:GMDA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. View Gamida Cell's Earnings History.

Gamida Cell is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Gamida Cell.

2 Wall Street analysts have issued 1-year target prices for Gamida Cell's shares. Their forecasts range from $16.00 to $18.00. On average, they expect Gamida Cell's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Gamida Cell.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.

News coverage about GMDA stock has trended somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gamida Cell earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the next several days. View News Stories for Gamida Cell.

Gamida Cell saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 44,800 shares, a decline of 5.1% from the October 31st total of 47,200 shares. Based on an average trading volume of 30,300 shares, the short-interest ratio is currently 1.5 days. Currently, 0.4% of the shares of the stock are sold short. View Gamida Cell's Current Options Chain.

Some companies that are related to Gamida Cell include Innate Pharma (IPHA), Harpoon Therapeutics (HARP), Replimune Group (REPL), Tcr2 Therapeutics (TCRR), BioCryst Pharmaceuticals (BCRX), Oyster Point Pharma (OYST), Cellular Biomedicine Group (CBMG), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Eiger Biopharmaceuticals (EIGR), CASI Pharmaceuticals (CASI), Compugen (CGEN), Jounce Therapeutics (JNCE), ADMA Biologics (ADMA) and Scholar Rock (SRRK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Palatin Technologies (PTN), Celgene (CELG), Cisco Systems (CSCO), LYFT (LYFT), Outlook Therapeutics (OTLK), Ovid Therapeutics (OVID), PhaseBio Pharmaceuticals (PHAS), Spring Bank Pharmaceuticals (SBPH), AcelRx Pharmaceuticals (ACRX) and Antares Pharma (ATRS).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.29%) and Phoenix Holdings Ltd. (0.12%).

GMDA stock was acquired by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Millennium Management LLC.

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $5.10.

Gamida Cell has a market capitalization of $123.53 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.

The official website for Gamida Cell is http://www.gamida-cell.com/.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]